GlassScriptPhysician profile
Jessica E Yan
NPI 1881956191
$823.47
in general payments reported to CMS, 2019-2025
17 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2022: $16.23 · 2024: $119 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $188.36 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $93.58 | 2019-2025 | Opdualag |
| Celgene Corporation | $86.24 | 2025 | Reblozyl |
| Janssen Biotech, INC. | $61.99 | 2025 | Carvykti, Talvey, Darzalex |
| Abbvie INC. | $54.56 | 2024-2025 | |
| Incyte Corporation | $51.85 | 2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $42.20 | 2025 | Columvi, Tecentriq |
| Pfizer INC. | $33.39 | 2019-2024 | |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Dendreon Pharmaceuticals LLC | $29.91 | 2025 | Provenge |
| Alexion Pharmaceuticals, INC. | $25.05 | 2019 | |
| Glaxosmithkline, LLC. | $25.00 | 2019 | |
| Daiichi Sankyo INC. | $24.41 | 2024 | Enhertu |
| Genzyme Corporation | $23.51 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.42 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.60 | 2025 | |
| Tactile Systems Technology INC | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.